STERTZER SIMON H purchased $104K of BCDA

STERTZER SIMON H purchased 109,200 shares of BioCardia, Inc. (BCDA) at an average of $0.95 ($0.92–$1.00, $0.10M total) across 2 trades over 2026-06-22 to 2026-06-23.

Original reporting
SEC EDGAR · STERTZER SIMON H
Published Jun 24, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BCDA
Neutral
medium confidence
Mentioned
$BCDA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDANeutralLow
01

Why it matters

This is a primary-source insider buy, but it does not include new company performance, guidance, trial results, or regulatory actions that would typically drive repricing.

02

Market read

Traders may note the insider buy as a sentiment datapoint, but the filing alone is unlikely to change valuation without accompanying fundamental catalysts.

03

What to watch

No 10b5-1 plan is cited, but the article also provides no context on prior holdings, option exercises, or whether the director’s purchase was part of a broader pattern.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed June 24, covering trades from June 22-23.

Background

The article is an SEC Form 4 insider transaction disclosure for BioCardia, Inc. (BCDA) by a director.

Company-level read

Ticker impact

$BCDANeutralMedium confidence
Context

BioCardia director Simon H Stertzer reported an open-market purchase of 109,200 shares at $0.9200 to $1.0000 between June 22-23.

Expected impact

Likely limited near-term impact; any effect is more sentiment than new business information.

Evidence & confidence

Insider buys can be read as confidence, but this filing provides no new operational or financial metrics, and the transaction occurred days before the filing date.

Market effects

No clear sector read-through because the disclosure is a single-company insider transaction without new clinical or regulatory information.

None indicated.

None indicated.

Counterpoint

The buy may reflect routine liquidity needs, diversification, or non-informational timing rather than a change in outlook.

Key entities

  • BioCardia, Inc.

    Company whose director reported an open-market purchase of shares via SEC Form 4.

  • STERTZER SIMON H

    Director who purchased 109,200 shares across two trades at $0.9200 to $1.0000.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BCDAMed

BioCardia Inc (BCDA) (Q3 2026) Earnings Call Highlights: Japan Shonin Submission Advances

BioCardia Inc (BCDA) reported Q3 2026 earnings, highlighting progress in Japan's Shonin submission for CardiAMP Cell Therapy, expected within months. CEO Peter Altman discussed partnerships, regulatory pathways, and clinical trial updates. The company reported $1.7M in net cash used in operations, with $2.2M in cash reserves. Key catalysts include FDA feedback on the Helix catheter system and potential gene therapy partnerships.

$BCDAMedAI 8/10

BioCardia’s CardiAMP Completes Japan Pre-Market Consultation, First Cardiac Cell Therapy to Do So

BioCardia (BCDA) completed Japan's PMDA consultation for its CardiAMP Cell Therapy System, positioning it for a marketing approval application. The therapy, which uses a patient's own bone marrow cells, aims to treat heart damage. BioCardia targets a formal submission by late 2026 and commercial revenue by 2028. The company's Phase 3 trial showed significant improvements in a subgroup of patients with elevated NTproBNP levels, which PMDA has reviewed positively.

$BCDAMed

BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application SUNNYVALE, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. (NASDAQ: BCDA) , a global le

$BCDAMedAI 8/10

BioCardia Advances Helix Catheter Toward FDA Marketing Clearance

BioCardia (BCDA) submitted a revised De Novo pre-submission package to the FDA for its Helix catheter, following feedback. The FDA accepted the submission and expects review, feedback, and a meeting in Q4 2026. The catheter is designed for delivering therapeutic agents to heart muscle and has clinical safety data from 15 trials. FDA clearance could expand partnership opportunities for BCDA.